230 / 1578
/
Ø
Very limited gain in TCP for doses >100Gy BED
Grills JTO 2010; Ohiri IJROBP 2012
0
20
40
60
80 100 120 140 160 180 200
BED
10
Perscription dose PTV (Gy)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Local control
Guckenberger Radiother Oncol 2013
= 3 x 18Gy
What dose is now actually required?
n=505
n=395
07.09.17
Matthias Guckenberger - ESTRO SBRT Course 2017
17
/
Late recurrences in stage I NSCLC
• Very few recurrences after 3 – 5 years
Ø
Validity of TCP modelling
Swedish phase II trial:
N=57
Japanese prospective study:
N=180
Lindberg Acta Oncol 2015
Shibamoto JTO 2015
Median FU 41.5 months
3 x 15Gy @ 67%
Median FU 52.5 months
4 x 11-13 Gy @ isocenter
07.09.17
Matthias Guckenberger - ESTRO SBRT Course 2017
18